Arcutis Biotherapeutics, Inc. Common Stock ARQT
Analyst Ratings
- Consensus
- Buy — 6 Buy · 1 Hold · 0 Sell (7 analysts)
- Avg. Price Target
- $35.57 (+46.7% upside)
Key Stats
- Today's Range
- $23.79 – $24.50
- 50-Day Range
- $23.21 – $29.84
- 52-Week Range
- $14.03 – $31.77
- Volume
- 619K shs
- Average Volume
- 1.85 million shs
- Market Cap
- $3.00 billion
- P/E Ratio
- 115.48
- Dividend Yield
- —
Valuation
- P/E Ratio
- 115.48
- Price / Book
- 13.61
- Price / Sales
- 6.47
Short Interest
- Short Interest
- 0.19%
- Days to Cover
- 1.16
Financials (TTM)
- Revenue
- $463.98 million
- Net Income
- $28.52 million
- Net Margin
- 6.15%
- Return on Equity
- 12.93%
- Debt-to-Equity
- 0.49
About Arcutis Biotherapeutics, Inc. Common Stock
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Related Stocks
Compare head-to-head: ARQT vs LLY·ARQT vs JNJ·ARQT vs ABBV·ARQT vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.